Aker ASA A Shs (AKAAF) 24.0407 $AKAAF
Bregal Partners Sponsors Deleveraging Recapitalization of American Seafoods
BusinessWire - Thu Aug 20, 5:00AM CDT
American Seafoods, the largest harvester of wild-caught fish for human consumption in the U.S., announced today that it has closed a deleveraging recapitalization. The transaction was sponsored by Bregal Partners, as well as Pacific Seafood Group and other industry investors, and it includes a significant equity capital infusion and a refinancing of the Company's outstanding debt. The deleveraging recapitalization significantly reduces the Company's indebtedness, establishes stable, long-term financing, and provides the Company with a patient and strategic investor base, strengthening its position as a leading provider of sustainable seafood products.
Matts Johansen to take over as CEO of Aker BioMarine from Hallvard Muri
M2 - Thu Jun 11, 8:00AM CDT
Aker BioMarine today announced that Hallvard Muri has chosen to step down as chief executive officer of Aker BioMarine after close to seven years in the position. Muri will join the company's board of directors. Muri, who has worked in the Aker group since 2002, will go on to pursue other projects within the Aker group.
Inspirion Delivery Technologies Announces FDA Acceptance of MorphaBond(TM) ER (morphine sulfate extended-release) New Drug Application; Its Investigational Abuse-Deterrent, Extended-Release Opioid
PR Newswire - Mon Feb 09, 7:25PM CST
Inspirion Delivery Technologies, LLC ("IDT"
, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group ("TPG", announced that the U.S. Food & Drug Administration ("FDA" has accepted for filing the New Drug Application ("NDA" submitted on November 21, 2014 for its investigational drug, MorphaBond(TM) ER, an extended-release (ER), abuse-deterrent formulation of morphine. MorphaBond ER is an opioid analgesic, utilizing IDT's patent-protected, proprietary technology. This NDA requests FDA approval of MorphaBond ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. TPG, the Norwegian based 50/50 joint venture between Aker ASA and Lindsay Goldberg LLC, is IDTs investment partner in a number of opioid development programs, including MorphaBond ER.
Bregal Partners Sponsors Deleveraging Recapitalization of American Seafoods
BusinessWire - Thu Aug 20, 5:00AM CDT
American Seafoods, the largest harvester of wild-caught fish for human consumption in the U.S., announced today that it has closed a deleveraging recapitalization. The transaction was sponsored by Bregal Partners, as well as Pacific Seafood Group and other industry investors, and it includes a significant equity capital infusion and a refinancing of the Company's outstanding debt. The deleveraging recapitalization significantly reduces the Company's indebtedness, establishes stable, long-term financing, and provides the Company with a patient and strategic investor base, strengthening its position as a leading provider of sustainable seafood products.
Matts Johansen to take over as CEO of Aker BioMarine from Hallvard Muri
M2 - Thu Jun 11, 8:00AM CDT
Aker BioMarine today announced that Hallvard Muri has chosen to step down as chief executive officer of Aker BioMarine after close to seven years in the position. Muri will join the company's board of directors. Muri, who has worked in the Aker group since 2002, will go on to pursue other projects within the Aker group.
Inspirion Delivery Technologies Announces FDA Acceptance of MorphaBond(TM) ER (morphine sulfate extended-release) New Drug Application; Its Investigational Abuse-Deterrent, Extended-Release Opioid
PR Newswire - Mon Feb 09, 7:25PM CST
Inspirion Delivery Technologies, LLC ("IDT"
, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group ("TPG", announced that the U.S. Food & Drug Administration ("FDA" has accepted for filing the New Drug Application ("NDA" submitted on November 21, 2014 for its investigational drug, MorphaBond(TM) ER, an extended-release (ER), abuse-deterrent formulation of morphine. MorphaBond ER is an opioid analgesic, utilizing IDT's patent-protected, proprietary technology. This NDA requests FDA approval of MorphaBond ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. TPG, the Norwegian based 50/50 joint venture between Aker ASA and Lindsay Goldberg LLC, is IDTs investment partner in a number of opioid development programs, including MorphaBond ER. 
